Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Centessa Pharmaceuticals (CNTA) EBIT Margin (2022 - 2025)

Historic EBIT Margin for Centessa Pharmaceuticals (CNTA) over the last 3 years, with Q1 2025 value amounting to 205.18%.

  • Centessa Pharmaceuticals' EBIT Margin changed N/A to 205.18% in Q1 2025 from the same period last year, while for Sep 2025 it was 1425.33%, marking a year-over-year decrease of 77153300.0%. This contributed to the annual value of 2499.39% for FY2023, which is N/A changed from last year.
  • Latest data reveals that Centessa Pharmaceuticals reported EBIT Margin of 205.18% as of Q1 2025.
  • In the past 5 years, Centessa Pharmaceuticals' EBIT Margin ranged from a high of 4138.78% in Q2 2022 and a low of 205.18% during Q1 2025
  • Its 3-year average for EBIT Margin is 2097.27%, with a median of 1919.14% in 2023.
  • Over the last 5 years, Centessa Pharmaceuticals' EBIT Margin had its largest YoY gain of -5196800bps in 2023, and its largest YoY loss of -22196400bps in 2023.
  • Quarter analysis of 3 years shows Centessa Pharmaceuticals' EBIT Margin stood at 1888.47% in 2022, then decreased by -28bps to 1368.79% in 2023, then plummeted by -115bps to 205.18% in 2025.
  • Its EBIT Margin was 205.18% in Q1 2025, compared to 1368.79% in Q4 2023 and 1582.41% in Q3 2023.